TRT Bloodwork Guide: Complete Lab Testing for Testosterone Therapy

Introduction: Why Bloodwork Matters for TRT

Testosterone replacement therapy (TRT) is a hormone intervention with profound effects on multiple body systems. Comprehensive blood work monitoring ensures safety, optimizes therapy, and identifies potential complications before they become clinically significant. This guide outlines essential laboratory assessments for patients initiating and maintaining TRT.

Pre-Treatment Baseline Bloodwork

Before initiating TRT, comprehensive baseline assessment is essential to establish normal hormone levels, identify contraindications, and provide comparison points for future monitoring.

Essential Pre-Treatment Labs

Hormonal Assessment

Total Testosterone (TT)

• Method: Serum measurement (blood draw)
• Normal range: 300-1000 ng/dL (most labs); optimal for replacement assessment: <300 ng/dL
• Why it matters: Establishes baseline deficiency; some patients have low-normal levels contributing to symptoms
• Timing: Draw between 7-10 AM when testosterone peaks
• Research note: Studies indicate testosterone naturally declines 1% annually after age 30; baseline assessment guides replacement strategy

Free Testosterone

• Method: Serum measurement (not salivary)
• Normal range: 50-210 pg/mL depending on assay
• Why it matters: Represents bioavailable testosterone; many symptomatic individuals have low free T despite normal total T
• Timing: 7-10 AM (AM levels are highest)
• Research note: Free testosterone better correlates with androgen receptor effect than total testosterone

Luteinizing Hormone (LH)

• Normal range: 1.5-9.3 mIU/mL
• Why it matters: Indicates hypothalamic-pituitary function; low LH with low T suggests central hypogonadism
• Timing: 7-10 AM
• Research note: LH suppression is expected on exogenous testosterone; baseline levels guide replacement strategy

Follicle-Stimulating Hormone (FSH)

• Normal range: 1.5-12.4 mIU/mL
• Why it matters: Indicates testicular function and fertility status
• Timing: 7-10 AM
• Research note: FSH suppression on TRT is expected; low baseline FSH predicts greater fertility impact

Estradiol (E2)

• Method: High-sensitivity assay (LC-MS/MS preferred)
• Normal range: 10-40 pg/mL (variable by lab and assay)
• Why it matters: Elevated baseline E2 predicts higher E2 on testosterone; guides aromatase inhibitor decisions
• Timing: 7-10 AM
• Research note: Studies indicate estradiol balance is critical for bone health, mood, erectile function on TRT

Prolactin

• Normal range: 2-18 ng/mL
• Why it matters: Elevated prolactin can cause erectile dysfunction and low libido
• Timing: Can be drawn anytime
• Research note: TRT may slightly elevate prolactin; baseline assessment helps interpret on-treatment values

Metabolic and Safety Assessment

Complete Metabolic Panel (CMP)

• Fasting glucose: 70-100 mg/dL
• Blood urea nitrogen (BUN): 7-20 mg/dL
• Creatinine: 0.7-1.3 mg/dL
• Estimated glomerular filtration rate (eGFR): >60 mL/min/1.73m²
• Electrolytes: Sodium, potassium, chloride, CO2
• Why it matters: Establishes baseline kidney function; testosterone can affect electrolytes

Liver Function Tests (LFTs)

• AST: 10-40 U/L
• ALT: 7-56 U/L
• Alkaline phosphatase: 40-130 U/L
• Bilirubin: 0.1-1.2 mg/dL (total)
• Why it matters: Baseline assessment before TRT initiation; some formulations affect liver function

Lipid Panel (Fasting)

• Total cholesterol: <200 mg/dL optimal
• HDL cholesterol: >40 mg/dL (men)
• LDL cholesterol: <100 mg/dL optimal
• Triglycerides: <150 mg/dL
• Why it matters: TRT may lower HDL and raise triglycerides; baseline essential for monitoring

Hemoglobin and Hematocrit

• Hemoglobin: 13.5-17.5 g/dL (men)
• Hematocrit: 41%-53% (men)
• Why it matters: Testosterone increases RBC production; elevated hematocrit is common on TRT
• Research note: Studies show hematocrit increases in 20-40% of TRT patients; monitored closely

Complete Blood Count (CBC)

• WBC, RBC, platelets, differential
• Why it matters: Establishes baseline; polycythemia monitoring baseline

Cardiovascular and Metabolic Health

Blood Pressure

• <120/80 mmHg optimal
• Why it matters: Testosterone can modestly raise blood pressure; baseline for comparison

Fasting Glucose and HbA1c

• Fasting glucose: 70-100 mg/dL
• HbA1c: <5.7% normal
• Why it matters: TRT may improve insulin sensitivity; baseline for metabolic monitoring
• Research note: Studies suggest TRT improves glucose control in some individuals

Additional Baseline Assessments

Prostate-Specific Antigen (PSA)

• Normal baseline: <4.0 ng/mL
• Why it matters: Establishes baseline for monitoring prostate health on TRT
• Research note: Testosterone does not cause prostate cancer, but may accelerate existing disease; baseline essential
• Timing: Can be drawn anytime (not affected by time of day)

Digital Rectal Exam (DRE)

• Performed by healthcare provider
• Why it matters: Assesses prostate size, nodules, abnormalities
• Research note: Baseline DRE important for detecting occult prostate pathology before TRT

Thyroid Panel

• TSH: 0.4-4.0 mIU/L
• Free T4: 0.8-1.8 ng/dL
• Why it matters: Thyroid dysfunction can mimic hypogonadism symptoms; baseline assessment important

Bone Density Screening (Age >50 or Risk Factors)

• Dual-energy X-ray absorptiometry (DXA) scan
• Why it matters: Baseline for osteoporosis/osteopenia; testosterone improves bone density
• Research note: TRT increases bone mineral density, particularly in spine and hip

Pre-Treatment Screening Summary

| Test | Normal Range | Purpose | |------|--------------|---------| | Total Testosterone | 300-1000 ng/dL | Assess deficiency | | Free Testosterone | 50-210 pg/mL | Bioavailable hormone | | LH | 1.5-9.3 mIU/mL | HPG axis assessment | | FSH | 1.5-12.4 mIU/mL | Fertility/testicular function | | Estradiol | 10-40 pg/mL | Aromatization baseline | | Prolactin | 2-18 ng/mL | Hypogonadism causes | | CMP | Various | Kidney/metabolic function | | Lipid panel | See section | Cardiovascular risk | | CBC | Various | Baseline RBC, polycythemia | | PSA | <4.0 ng/mL | Prostate baseline | | Thyroid panel | TSH 0.4-4.0 | Rule out thyroid dysfunction |

Optimal Testosterone Levels on TRT

Understanding target testosterone ranges is critical for effective treatment.

Total Testosterone Targets

Research indicates optimal total testosterone levels on TRT are:

• Replacement goal: 500-800 ng/dL (middle of normal range)
• Common TRT maintenance: 600-900 ng/dL
• Upper therapeutic limit: <1000-1200 ng/dL (approach with caution)
• Supraphysiologic range: >1200 ng/dL (associated with increased adverse effects)

Free Testosterone Targets

Free testosterone correlates more closely with androgen effects:

• Optimal range: 150-250 pg/mL (upper-middle of normal range)
• Functional minimum: 100-120 pg/mL
• Research note: Some studies suggest free T correlates better with mood, sexual function, and lean mass gains

Important Considerations

Why Not Maximize Testosterone? Research indicates supraphysiologic testosterone (>1200 ng/dL) increases risks of:

• Polycythemia (elevated RBC/hematocrit)
• Cardiovascular events (hypertension, fluid retention)
• Aromatization (higher estradiol)
• Prostate acceleration (in susceptible individuals)
• Liver stress
• Lipid deterioration

The Goldilocks Principle: Research suggests "just right" testosterone is:

• High enough to relieve hypogonadal symptoms
• Low enough to maintain health and avoid complications
• Individualized based on response and tolerance

On-Treatment Monitoring Schedule

Initial Titration Phase (First 3-6 Months)

| Timepoint | Labs | Purpose | |-----------|------|---------| | Baseline (pre-TRT) | Full panel (see section above) | Establish baseline | | 4-6 weeks | Total T, Free T, Estradiol, Hematocrit | Dose optimization | | 8-10 weeks | Total T, Free T, Estradiol, Hematocrit | Mid-adjustment assessment | | 12 weeks | Full panel (hormones, metabolic, lipids, PSA) | Comprehensive check-in | | 16 weeks | Total T, Free T, Estradiol, Hematocrit | Fine-tuning | | 24 weeks | Full panel | Confirm stability, metabolic effects |

Timing of Blood Draws During Titration:

• Draw 48-72 hours after injection (testosterone peak-to-trough assessment)
• Some providers draw at same time each week for consistency
• Research suggests mid-cycle levels most relevant to clinical response

Maintenance Phase (After Dose Established)

Most Common Monitoring Pattern:

• Every 6-12 months: Full panel including hormone levels, metabolic markers, lipids, CBC, PSA
• Annually: Cardiovascular assessment (blood pressure, lipid review, ECG if indicated)
• Every 3-5 years: Bone density assessment (DXA) in appropriate populations

More Frequent Monitoring (Every 3-6 Months) if:

• Polycythemia present (hematocrit >52-54%)
• Cardiovascular risk factors
• Metabolic abnormalities (elevated glucose, lipid changes)
• Age >60 years
• Concurrent aromatase inhibitor or HCG use
• New medications interacting with testosterone metabolism

Key Markers on TRT and Interpretation

Total and Free Testosterone

Expected Pattern:

• Increase within 2-4 weeks of TRT initiation
• Plateau at 4-8 weeks at stable dose
• Should be drawn 48-72 hours post-injection (or 3-7 days for long-acting ester)

Optimization Approach:

• If insufficient response at 4-6 weeks: Increase dose
• If supraphysiologic: Reduce dose
• Allow 4-6 weeks at each dose before reassessment

Research Note: Studies indicate testosterone response follows individual variation in absorption, metabolism, and SHBG binding.

Estradiol: The Balance Challenge

Estradiol management is central to TRT optimization.

Estradiol Range on TRT:

• Optimal: 20-35 pg/mL
• Acceptable: 15-50 pg/mL
• High: >50 pg/mL (manage if symptomatic)
• Very High: >70 pg/mL (consider intervention)

High Estradiol Symptoms:

• Water retention/bloating
• Gynecomastia (breast tissue development)
• Sexual dysfunction
• Mood changes (irritability, anxiety)
• Fat deposition (abdominal, chest)

Low Estradiol Concerns:

• Joint/tendon pain (estradiol essential for collagen synthesis)
• Erectile dysfunction
• Mood depression
• Bone density loss
• Cardiovascular risks

Management of Elevated Estradiol:

• First-line: Reduce testosterone dose (most physiologic)
• Aromatase Inhibitors (AIs):
  • Anastrozole (Arimidex): 0.5-1.0 mg daily or 1-2x weekly
  • Letrozole (Femara): 1.25-2.5 mg daily
  • Research indicates 25-40% dose reduction needed with AIs
  • Dosing must be individualized; monitor with repeat testing

Hematocrit: Polycythemia Monitoring

Polycythemia (elevated hematocrit/hemoglobin) is one of the most common TRT-related adverse effects.

Monitoring Parameters:

• Baseline hemoglobin: Establish pre-TRT level
• Baseline hematocrit: Establish pre-TRT level
• On-TRT acceptable range: <50-52% hematocrit
• Action threshold: >52-54% hematocrit (discuss intervention)

Polycythemia Management:

• Reduce testosterone dose (most effective approach)
• Increase physical activity (particularly aerobic exercise)
• Blood donation: Donate 1-2 pints every 3-6 months if needed
• Hydration: Ensure adequate water intake (2-3L daily)
• Research note: Studies indicate phlebotomy and dose reduction most effective

Why Monitor Hematocrit? Research suggests elevated hematocrit increases:

• Blood viscosity (thickness)
• Thrombotic risk (blood clots)
• Cardiovascular event risk
• Hypertension

Lipid Panel Changes

Testosterone influences lipid metabolism; monitoring for adverse changes is important.

Expected Changes on TRT:

• HDL reduction: 5-10% decrease common (this is the primary concern)
• LDL: Variable changes; some increase, some decrease
• Triglycerides: Usually stable or improve
• Total cholesterol: Modest increases possible

Management of Lipid Deterioration:

• Cardiovascular exercise (150+ min/week aerobic activity)
• Mediterranean-style diet (emphasize healthy fats)
• Reduce saturated fat intake
• Consider dose reduction if changes significant
• Statin therapy if cardiovascular risk warrants

Research Note: Studies show lipid changes are dose-dependent; supraphysiologic testosterone causes greater HDL reduction.

Prostate Health Markers

PSA Monitoring:

• Draw PSA at baseline and then every 6-12 months
• PSA elevation expected (typically 20-50% increase)
• Most patients stabilize in 6-12 months
• Rapid PSA increase (>0.75 ng/mL/year) warrants investigation

PSA Interpretation on TRT:

• TRT does not cause prostate cancer
• Research suggests TRT may accelerate pre-existing disease
• Rapid increase suggests need for urology evaluation
• DRE may help assess structural abnormalities

| PSA Level (ng/mL) | Interpretation | |-------------------|----------------| | <2.5 | Very low risk | | 2.5-4.0 | Low risk; monitor annually | | 4.0-10.0 | Intermediate; may warrant urology referral | | >10.0 | Elevated; recommend urology evaluation |

LH and FSH Suppression

Expected Pattern:

• LH suppression to <0.5 mIU/mL (normal on exogenous testosterone)
• FSH suppression to <0.5 mIU/mL (expected)
• Complete suppression indicates adequate feedback inhibition

Why Monitor?

• Confirms effective TRT dosing
• Indicates degree of HPG axis suppression
• Guides fertility discussion (reversibility timeline)

Research Note: Studies indicate LH/FSH recovery upon TRT discontinuation takes 6-12 months; longer with prior duration.

Prolactin and Other Hormones

Prolactin Changes:

• Mild elevation (18-30 ng/mL) possible on higher testosterone
• Rarely clinically significant
• Elevated prolactin predicts erectile dysfunction risk
• Management: Reduce testosterone dose if symptomatic

Thyroid Function:

• Monitor TSH if symptoms warrant
• Some research suggests TRT improves thyroid function
• Hypothyroid patients may need adjusted levothyroxine doses on TRT

Complete Monitoring Panel Protocol

Recommended Annual Labs (Maintenance Phase)

HORMONAL ASSESSMENT:
- Total Testosterone
- Free Testosterone
- Estradiol (high-sensitivity assay)
- LH
- FSH
- Prolactin

METABOLIC/RENAL FUNCTION:
- Fasting glucose
- Hemoglobin A1C
- Complete metabolic panel
- eGFR (kidney function)

LIVER FUNCTION:
- AST, ALT, Alkaline phosphatase
- Bilirubin

LIPID PROFILE (Fasting):
- Total cholesterol
- LDL cholesterol
- HDL cholesterol
- Triglycerides

HEMATOLOGY:
- Hemoglobin
- Hematocrit
- Complete blood count

PROSTATE HEALTH:
- PSA (prostate-specific antigen)

CARDIOVASCULAR:
- Blood pressure
- Resting heart rate

Special Situations: Ancillary Medications

Aromatase Inhibitor Monitoring

When using aromatase inhibitors (anastrozole, letrozole):

Additional Labs:

• Estradiol (more frequent: every 4-6 weeks initially)
• LH (to assess suppression adequacy)
• Lipids (AI may worsen HDL)
• Bone markers (AI may affect bone density long-term)

Typical AI Monitoring:

• Check E2 2-3 weeks after dose adjustment
• Maintain target E2 20-35 pg/mL
• Research indicates 20-40% of TRT patients need AI

Human Chorionic Gonadotropin (HCG) Monitoring

If using HCG for fertility preservation:

Additional Labs:

• LH (should remain somewhat elevated with adequate HCG)
• FSH (less important with HCG)
• Testicular assessment (clinical exam for size)
• Semen analysis (if fertility is goal)

HCG Dosing Considerations:

• Typical dose: 500-2000 IU 2-3x weekly
• Research indicates HCG addition costs ~$100-300/month
• HCG may increase polycythemia risk

Interpreting Your Bloodwork

Red Flags Requiring Provider Discussion

Immediate attention:

• Hematocrit >55%
• PSA rise >1 ng/mL over one year
• Fasting glucose >126 mg/dL (diabetes range)
• Total cholesterol >240 with LDL >160
• Liver enzymes significantly elevated
• Prolactin >30 ng/mL
• Estradiol >60 pg/mL with symptoms

Within 1-2 weeks:

• Hematocrit 52-55%
• PSA 4.0-10.0 ng/mL
• Fasting glucose 100-125 mg/mL (prediabetes)
• Triglycerides >200 mg/dL
• Mild transaminase elevation

Monitor and discuss at next appointment:

• Mild changes in lipid profile
• Estradiol 40-60 pg/mL (asymptomatic)
• PSA mild elevation <0.5 ng/mL/year

How to Prepare Your Doctor Discussion

Bring to Appointments:

• All bloodwork results (current and historical)
• Symptom tracking log (mood, sexual function, energy, side effects)
• Questions about results and next steps
• Medication list (including ancillaries)

Key Questions:

1. Are my testosterone levels in optimal range?
2. Am I experiencing any concerning changes since last visit?
3. What's my cardiovascular and prostate risk trajectory?
4. Should we adjust my TRT dose or ancillaries?
5. When should my next bloodwork be?

Timing of Bloodwork: Critical Details

Injection Schedule Impact

For Weekly Injections (Testosterone Cypionate, Enanthate):

• Peak: 48-72 hours post-injection
• Trough: Just before next injection
• Recommended draw time: 48-72 hours post-injection or mid-week
• Consistency: Draw at same time relative to injection for comparison

For Long-Acting Compounds (Testosterone Undecanoate, Propionate):

• Adjust timing based on specific ester half-life
• Discuss with provider for optimal draw timing
• Peak-to-trough variation less with longer-acting esters

For Transdermal or Topical:

• Draw at stable time (after 4-6 weeks at stable dose)
• Timing less critical as less peak-trough variation
• Usually morning before application

Day of Week and Circadian Rhythms

Testosterone Circadian Rhythm:

• Testosterone peaks 6-8 AM
• Drops 20-30% by afternoon
• Drawing at consistent time improves comparison

Optimal Timing:

• 7-10 AM, 2-4 days after injection (for weekly injectables)
• Fasting (12-hour fast preferred for lipids, glucose)
• Same day of week if possible

Long-Term Monitoring: The 5-Year Perspective

Years 1-2: Optimization Phase

• Frequent labs (quarterly)
• Dose titration ongoing
• Establish tolerance/side effect patterns
• Baseline for long-term comparison

Years 2-5: Maintenance Phase

• Semi-annual to annual labs
• Dose typically stable
• Monitor for cumulative effects (lipids, hematocrit, prostate)
• Assess sustainability and long-term safety

Years 5+: Long-Term Surveillance

• Annual comprehensive labs
• Increased monitoring for age-related issues (cardiovascular, prostate)
• Bone density reassessment every 2-3 years
• Consider age-appropriate cancer screening

Research Note: Long-term TRT data indicates continued safety with appropriate monitoring; most adverse events occur in first 2-3 years during titration phase.

Conclusion: Bloodwork as Your Safety Net

Comprehensive bloodwork monitoring transforms TRT from a guesswork undertaking into a data-driven, safe intervention. Regular monitoring allows:

• Optimization of your testosterone dose
• Early detection of adverse effects
• Confirmation of health improvements
• Adjustment of ancillary medications
• Prevention of serious complications

Work closely with a knowledgeable TRT-experienced provider who will order appropriate labs, interpret results thoughtfully, and adjust your protocol based on objective data and your individual response.

For more information on hormone optimization, explore our guide on GLP-1 weight loss medications and our comparison of tirzepatide vs semaglutide.

---

Disclaimer: This content is educational and does not constitute medical advice. All medical decisions should be made with qualified healthcare providers who know your individual situation. While this guide aims for accuracy, blood work interpretation varies by individual and should be personalized by your medical team.